Addyi (Flibanserin) Missed-Dose Protocol: What to Do and When to Resume

Flibanserin (Addyi) is FDA-approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women. It is not the same drug as sildenafil (Viagra) or other on-demand medications, and it is not approved for postmenopausal women. The core missed-dose instruction is short: if you miss a bedtime dose, skip it and take your regular 100 mg dose the following night, without doubling. This is a direct instruction from the FDA-approved prescribing information, which requires bedtime-only dosing because of dose-related hypotension and syncope risk. Because flibanserin works through gradual changes in central serotonin and dopamine signaling rather than an acute effect, a single missed dose is unlikely to be clinically meaningful, but the drug's labeled effectiveness window assumes consistent nightly dosing.

Why bedtime dosing is not optional

The FDA label specifies bedtime administration because flibanserin can cause dose-dependent drops in blood pressure, dizziness, and sedation. Taking it while upright and active during the day increases the chance of a fall or fainting episode compared with taking it before sleep. This is the stated rationale behind the drug's Risk Evaluation and Mitigation Strategy (REMS): flibanserin can only be prescribed and dispensed by prescribers and pharmacies certified in that program, a structure the FDA put in place at approval in 2015 specifically because of the hypotension and syncope risk.

This means the missed-dose question is really a question about timing safety, not just adherence. Taking a forgotten dose in the morning or afternoon does not restore the intended safety margin, because the protective context (already lying down, going to sleep) is gone.

What to do if you miss a dose

The label instruction is direct: if a dose is missed at bedtime, take the next dose at the regular bedtime the following day, and do not double the next dose to make up for the missed one. There is no FDA-described scenario in which catching up on a missed flibanserin dose is appropriate.

The reasoning follows from how long the drug stays active. Flibanserin has a terminal half-life on the order of half a day, so a single missed dose clears the body's drug level well before the next scheduled dose. Doubling up the following night would push plasma levels meaningfully above the level tested in trials, and the trials that established flibanserin's side-effect profile were conducted at the labeled 100 mg once-nightly dose, not at higher or doubled exposure. There is no controlled evidence describing what a doubled dose does, only the general pharmacologic expectation that higher exposure raises hypotension and syncope risk.

Missed-dose and monitoring conversation guide

This is a structure for talking through a missed dose with a prescriber, not a substitute for individualized medical advice. It separates what the label states from decisions that require clinical judgment.

Step 1, Classify the miss

Step 2, Watch for escalation signs, regardless of adherence Contact a prescriber or seek urgent care for:

• Fainting, near-fainting, or a fall associated with dosing
• Severe dizziness, especially on standing
• New sedation that interferes with driving or waking safely
• Suspected double dosing (two tablets taken within the same dosing period), this warrants contacting a prescriber or emergency services and lying down, not driving

Step 3, Distinguish label guidance from individualized care The label sets the population-level rules: bedtime-only dosing, no doubling, no titration on restart, and an 8-week checkpoint to judge effect. A prescriber individualizes around that framework: adjusting for other medications that raise flibanserin levels, weighing whether missed doses invalidate a treatment trial, and deciding whether side effects are tolerable given the expected delay before any benefit appears. A missed-dose pattern that keeps recurring is itself clinical information worth bringing to an appointment, not just a logistics problem.

How missed doses interact with whether the drug is working

Flibanserin is not an as-needed medication. It is intended to be taken every night, and its proposed effect on desire depends on sustained rather than intermittent exposure to the drug's action on serotonin and dopamine pathways. The FDA label instructs prescribers to discontinue flibanserin if a patient reports no improvement after 8 weeks of use. That checkpoint assumes reasonably consistent nightly dosing across those 8 weeks.

If a patient has missed a substantial fraction of doses, an 8-week "it isn't working" conclusion is less reliable, because the trial conditions that established the drug's effect window involved a defined dosing schedule. In that situation, the more useful clinical question is whether the missed doses reflect a fixable adherence barrier (forgetfulness, a bedtime routine that doesn't fit the schedule, side effects making the patient reluctant to take it) versus a genuine lack of benefit at adequate adherence. This distinction is a clinical judgment call, not something the label spells out numerically, and it is worth raising explicitly with a prescriber rather than assuming either conclusion.

Mechanism, briefly, and why timing consistency matters

Flibanserin acts on the brain rather than on genital blood flow. It functions as a serotonin 5-HT1A receptor agonist and a 5-HT2A receptor antagonist, with reported downstream effects on dopamine and norepinephrine signaling in brain regions implicated in sexual desire. This is mechanistically different from on-demand PDE5 inhibitors like sildenafil, which act peripherally within an hour and are taken only when needed. Flibanserin's central, receptor-based mechanism is the reason it is dosed daily rather than as needed, and why its designers built in a multi-week evaluation period rather than an immediate one. Receptor-level adaptations of this kind are generally understood to take on the order of weeks to stabilize, similar to some antidepressant mechanisms, though the exact time course specific to flibanserin's effect on desire is described qualitatively in FDA materials rather than as a precise, independently reproduced number.

Alcohol: the interaction does not pause just because a dose is skipped

The FDA label carries a boxed warning about combining flibanserin with alcohol because the combination can cause severe hypotension and loss of consciousness. The labeled precaution is to avoid alcohol within a window before and after dosing.

On a night when the dose itself is skipped, the patient is not acutely exposed to flibanserin at that moment, since the prior dose has already cleared based on the drug's half-life. That is not a green light for unrestricted alcohol use, and it does not change the interaction risk once dosing resumes. A common timing error is drinking the evening after a missed dose and then taking that night's flibanserin dose too soon afterward. The label's alcohol-timing restriction applies to every dose taken, independent of whether the previous night's dose was skipped.

Drug interactions that make dosing errors more dangerous

Flibanserin is metabolized primarily through the CYP3A4 enzyme pathway. The label lists strong CYP3A4 inhibitors (certain antifungals, certain antibiotics, some HIV protease inhibitors) as contraindicated because they substantially raise flibanserin blood levels, and it lists moderate CYP3A4 inhibitors as requiring caution. Because current labeling can be updated, the exact numeric fold-increase for a given inhibitor should be confirmed against the current FDA label or a pharmacist rather than assumed from memory. The practical point for missed-dose handling is that patients on any CYP3A4 inhibitor have less margin for error: an accidental double dose in that context carries a meaningfully higher risk than the same error in someone not taking an interacting medication. Medication reconciliation, including over-the-counter and herbal products, is worth revisiting at every refill.

Restarting after stopping for a while

The FDA label does not describe a special re-titration schedule for restarting flibanserin after a gap. The approved dose is 100 mg at bedtime from the first resumed dose; a lower starting dose was not the effective dose established in the drug's development program.

Patients restarting should expect three things drawn directly from the label's logic: the alcohol-timing restriction applies from the first dose back, the drug again requires several weeks of consistent dosing before any effect on desire can reasonably be judged, and REMS program requirements remain in effect for as long as the medication is used. If a prior discontinuation was due to side effects such as dizziness, somnolence, or nausea, that history is worth discussing with a prescriber before restarting, given that any benefit is not expected quickly.

What is established, what is plausible, and what is not established

Established, from the FDA label: bedtime-only dosing, the skip-and-resume missed-dose instruction, the boxed alcohol warning, the CYP3A4 contraindication category, and the 8-week discontinue-if-no-improvement guidance.

Plausible but not rigorously quantified in the material reviewed here: how many missed doses meaningfully delay or blunt the treatment effect, and the precise time course of receptor-level adaptation specific to flibanserin's desire effect. These are reasonable pharmacologic inferences, not numbers with a clean citation in this review.

Not established: any claim about outcomes from doubling a dose, since that scenario was not the tested condition in the drug's approval studies. Individualized dosing decisions, and whether a particular patient's missed-dose pattern should change her treatment plan, require a conversation with her own prescriber rather than a general protocol.

This article summarizes FDA labeling and general pharmacology for educational purposes. It does not replace individualized advice from the prescriber managing your care, and any decision about adjusting, stopping, or restarting flibanserin should be made with that prescriber, particularly if you are also taking other medications that affect CYP3A4 metabolism.